Sign in Subscribe

crc-research

A collection of 699 issues

Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease

Skip to content The CRC Digest ♥ LIVING WITH CRC Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial examined quality of life in patients with RAS wild-type metastatic colorectal cancer

Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab

Skip to content The CRC Digest ▸ TREATMENT Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab A multicenter study across 19 Spanish hospitals evaluated real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer after at least two prior treatment regimens. (ESMO Gastrointestinal

FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027

Skip to content The CRC Digest ● REGULATORY FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027 The FDA has extended its approval decision for Exelixis' oral kinase inhibitor zanzalintinib in combination with Roche's Tecentriq to March 2027 while awaiting updated safety and

CRC Research Finding

Skip to content The CRC Digest ● REGULATORY This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

CRC Research Update — September 12, 2026

Today's colorectal cancer research highlights

PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy

Skip to content The CRC Digest ▸ TREATMENT PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy The PRECAM-R trial demonstrated that short-course radiotherapy may create an immune-priming window in microsatellite-stable tumors, allowing PD-L1 blockade to achieve a 44.8% pathologic complete response rate. (The ASCO

39-year-old proband with Lynch syndrome shows discordant tumor testing

Skip to content The CRC Digest ◇ RESEARCH 39-year-old proband with Lynch syndrome shows discordant tumor testing A 39-year-old man with colorectal cancer and family history fulfilling Amsterdam criteria carried the germline MLH1 c.931A>G variant, with tumors showing MSI-H status despite retained MMR protein expression. (Clinical Case Reports)

Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining

Skip to content The CRC Digest ◇ RESEARCH Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining A family carrying germline MLH1 c.931A>G presented with colorectal tumors showing retained mismatch repair protein expression by immunohistochemistry but microsatellite instability-high status on sequencing, highlighting that preserved staining does

Study evaluates follow-up after positive stool-based screening in rural populations

Skip to content The CRC Digest ▪ SCREENING Study evaluates follow-up after positive stool-based screening in rural populations (The American Surgeon) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Collision tumor case reveals dual primary colorectal cancers with distinct molecular profiles

Skip to content The CRC Digest ◇ RESEARCH Collision tumor case reveals dual primary colorectal cancers with distinct molecular profiles Researchers report a rare collision tumor composed of two adjacent primary colorectal carcinomas, one harboring a TPR::NTRK fusion with MSI-H and high tumor mutational burden, the other showing conventional adenocarcinoma